Aims To determine tolerability and the optimal dose regimen of the soluble guanylate
cyclase stimulator vericiguat in patients with chronic heart failure and preserved ejection …

Aims Exploratory assessment of the potential benefits of the novel soluble guanylate cyclase
stimulator vericiguat on health status in patients with heart failure (HF) with preserved …

Background The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in
patients with heart failure and reduced ejection fraction who had recently been hospitalized …

Importance Worsening chronic heart failure (HF) is a major public health problem. Objective
To determine the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase …

Aims The clinical outcomes for patients with worsening chronic heart failure (WCHF) remain
exceedingly poor despite contemporary evidence‐based therapies, and effective therapies …

Importance Patients with heart failure and preserved ejection fraction (HFpEF) are at high
risk of mortality, hospitalizations, and reduced functional capacity and quality of life …

This trial sought to evaluate whether vericiguat, a novel oral soluble guanylate cyclase
(sGC) stimulator, was superior to placebo, on a background of standard of care, in …

Abstract Vericiguat (VERQUVO™; Merck & Co, Bayer AG) is a soluble guanylate cyclase
(sGC) stimulator being developed for the treatment of chronic heart failure. Vericiguat …

Introduction The significant morbidity and mortality in patients with heart failure (HF), notably
in the most advanced forms of the disease, justify the need for novel therapeutic options. In …

Aims Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic
peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure …